Company / Return on Assets (ROA)
Neurocrine Biosciences Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
10.3%
FY2025
5-year range
4.3% / 17.2%
FY2021-FY2025
Trend
+12.5%
vs FY2024
Sector context
#28 of 213
Health Care
What the data says
Neurocrine Biosciences's return on assets (roa) of 10.3% is higher than 87% of companies in the Health Care sector (FY2025). Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -38.6% in FY2016 to 23.5% in FY2020.
Based on SEC 10-K filings.
10.3% in FY2025 with a 5-year CAGR of -13.2%. Top quartile in the Health Care sector.
Improved from 7.7% to 10.3% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -6.9pp
- 5-Year Change
- -13.2pp
- 10-Year Change
- -
Sector benchmark
+142.7% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 12.5% year-over-year.
- Currently 34.5pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
- Lowest return on assets (roa) in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 10.3% | +12.5% |
| FY2024 | 9.2% | +19.5% |
| FY2023 | 7.7% | -55.3% |
| FY2022 | 17.2% | +298.1% |
| FY2021 | 4.3% | -81.6% |
| FY2020 | 23.5% | +729.7% |
| FY2019 | 2.8% | +33.5% |
| FY2018 | 2.1% | +112.2% |
| FY2017 | -17.4% | +54.9% |
| FY2016 | -38.6% | -106.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026